The Series C will allow Proscia to invest in product development, accelerate the adoption of computational pathology and grow its team. It will also scale its commercial operations, including sales, marketing and support teams, and will grow its distribution partnerships following a recent agreement with Siemens Healthineers.
Featured Story:
Latest Articles
October 1, 2024